Investment Bank Rothschild Indicates Several Strong Points Of Cash-strapped Wockhardt
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Indian pharmaceutical and biotechnology company Wockhardt may be finding itself in an extremely tight financial condition due to its commitment to repay $110 million foreign currency convertible bonds by October and debts of more than $600 million it took for overseas acquisitions; however analysts remain upbeat on company strengths